BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16445828)

  • 21. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
    Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
    Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
    Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low versus high cell turnover in diffusely growing non-Hodgkin's lymphomas.
    Spina D; Leoncini L; Del Vecchio MT; Megha T; Minacci C; Poggi SA; Pileri S; Tosi P; Kraft R; Laissue JA
    J Pathol; 1995 Dec; 177(4):335-41. PubMed ID: 8568587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. cFLIP regulation of lymphocyte activation and development.
    Budd RC; Yeh WC; Tschopp J
    Nat Rev Immunol; 2006 Mar; 6(3):196-204. PubMed ID: 16498450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome.
    Valnet-Rabier MB; Challier B; Thiebault S; Angonin R; Margueritte G; Mougin C; Kantelip B; Deconinck E; Cahn JY; Fest T
    Br J Haematol; 2005 Mar; 128(6):767-73. PubMed ID: 15755279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features.
    Osoegawa A; Yoshino I; Kometani T; Yamaguchi M; Kameyama T; Yohena T; Maehara Y
    Cancer; 2006 Jul; 107(1):154-61. PubMed ID: 16721818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary thyroid non-Hodgkin's lymphomas: clinicopathological observations on patients living in the island of Crete.
    Kyriakou D; Bizakis J; Papadakis C; Sakellariou D; Tsardi M; Alexandrakis M; Chelidonis E; Eliopoulosi GD
    Haematologia (Budap); 1996; 27(3):129-33. PubMed ID: 14653449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
    Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
    Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
    Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
    Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
    Lee JJ; Kim DH; Lee NY; Sohn SK; Kim JG; Kim HJ; Do YR; Park YH
    Br J Haematol; 2007 May; 137(4):329-36. PubMed ID: 17408400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
    Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous cytomorphologic and multiparametric flow cytometric analysis on lymph node samples is faster than and as valid as histopathologic study to diagnose most non-Hodgkin lymphomas.
    Colorado M; Cuadrado MA; Insunza A; Mazorra F; Acinas O; Iriondo A
    Am J Clin Pathol; 2010 Jan; 133(1):83-91. PubMed ID: 20023262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
    Paiva M; Marques H; Martins A; Ferreira P; Catarino R; Medeiros R
    Cancer Genet Cytogenet; 2008 May; 183(1):35-40. PubMed ID: 18474295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic difficulties and treatment of non-Hodgkin lymphoma of the orbit.
    Wanyura H; Uliasz M; Kaminski A; Samolczyk-Wanyura D; Smolarz-Wojnowska A
    J Craniomaxillofac Surg; 2007 Jan; 35(1):39-47. PubMed ID: 17267230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting the outcome in non-Hodgkin lymphoma with molecular markers.
    Kwong YL
    Br J Haematol; 2007 May; 137(4):273-87. PubMed ID: 17408399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience.
    Biswas G; Parikh PM; Nair R; Bhagwat R; Bakshi A; Prabhash K; Vora A; Gupta S; Pai VR; Menon H; Sastry PS
    J Assoc Physicians India; 2006 Jan; 54():29-33. PubMed ID: 16649735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index.
    Vose JM; Bierman PJ; Loberiza FR; Lynch JC; Bociek GR; Weisenburger DD; Armitage JO
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):36-42. PubMed ID: 18158959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.